Wegovy vs Zepbound: The Head-to-Head

Wegovy vs Zepbound at a glance

Every row below is a decision variable for someone: results for the outcome-driven, self-pay price for the uninsured, bonus indications for anyone negotiating coverage. Scan for the rows that are live variables in your situation, then read the sections that expand them.

Trial percentages are average body weight lost at trial endpoint on maintenance doses; individual results spread widely around every average shown.

The results gap: six and a half points is real

SURMOUNT-5 matters because it removed the cross-trial guesswork: same study, same conditions, 20.2% versus 13.7%. The gap matches what the separate pivotal trials implied and is attributed to tirzepatide's dual GLP-1/GIP mechanism, unpacked in our molecule-level comparison.

Translation to a concrete case: from a 240 lb starting point, the trial averages correspond to roughly 33 lb versus 48 lb over the trial period. Two honest caveats travel with that math. Averages conceal wide individual spreads, and plenty of Wegovy patients outperform plenty of Zepbound patients. And a 13.7–15% average is itself a historically strong result, not a consolation prize; five years ago nothing on the market approached it.

Look past the averages to the distribution and the case for each drug sharpens. In tirzepatide trials, a substantially larger share of participants cleared the 20% threshold than semaglutide trials produce, which matters most for people with large total goals. At the other end, both drugs have strong and weak responders, and no test predicts in advance which you will be, an argument for choosing on price and coverage first, then letting measured response rather than brand loyalty drive any later switch.

The price fight: closer than the list prices suggest

At list, Zepbound looks cheaper, $1,086 versus $1,349, but list is the wrong lens. In the channels people actually use:

• Self-pay maintenance: effectively a tie at $499, Wegovy pens via NovoCare versus Zepbound vials via LillyDirect, with Zepbound's first month cheaper at $349.
• Format difference: Wegovy's $499 buys pens; Zepbound's buys vials and syringes. People who will not draw doses pay list or copay prices for Zepbound pens.
• Compounded undercuts both: semaglutide from ≈ $99, tirzepatide from ≈ $199, through the telehealth programs covered in the full price overview.
• Insured: $25–$50 either way; coverage, not price, decides.

Two secondary price details break the tie for some buyers. First-month cost: $349 versus $499 favors Zepbound during the period when many people are still deciding whether the category suits them at all. Billing rhythm: a flat rate means Wegovy's twelfth invoice equals its first, while Zepbound's steps up once at the move past 2.5 mg. Over a full year the totals converge; in the first ninety days, Zepbound is the cheaper experiment.

Bonus indications: the tiebreaker most people miss

Each drug carries a second FDA-approved indication, and for insured patients these are often the whole ballgame. Wegovy is approved for cardiovascular risk reduction in adults with established cardiovascular disease and elevated weight, the route through which Medicare, which excludes weight loss drugs as such, can cover it. Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, likewise opening coverage, including Medicare, where weight loss alone is excluded.

So the practical tiebreaker: documented cardiovascular disease tilts the board toward Wegovy; a sleep study showing OSA tilts it toward Zepbound. Either indication converts a typically denied claim into an on-label prior authorization, mechanics covered in the insurance playbook. Without either diagnosis, the decision reverts to cash price and effectiveness.

Documentation quality decides these routes in practice: a cardiology record with dated diagnoses for Wegovy, a scored sleep study for Zepbound. The indication is the door; the paperwork is the key, and assembling it before filing beats assembling it during an appeal.

The verdict, by situation

No single winner, but clean answers per profile:

• Cash payer optimizing results per dollar: Zepbound vials, higher average results at an equal-or-lower $349–$499.
• Cash payer who wants a pen, not a syringe: Wegovy at $499 flat via NovoCare.
• Cardiovascular history: Wegovy, for the coverage-unlocking indication.
• Diagnosed sleep apnea: Zepbound, same logic in reverse.
• Whichever your plan covers: that one; a $25–$50 copay beats every cash argument above.
• Tight budget: neither brand; compounded routes start near $99, per the cheapest semaglutide ranking.

The comparison also ages differently on each side. Wegovy's position rests on a flat price and the cardiovascular indication; Zepbound's on superior averages and the cheaper vial entry. Neither advantage is fragile, but formularies re-tier these drugs annually and both manufacturers have shown willingness to reprice their direct channels, so a decision made this year deserves a fresh price check at renewal rather than automatic continuation.

Both require the same eligibility, BMI 30-plus or 27 with a comorbidity, judged by a licensed provider. To compare both drugs' current program pricing side by side, check today's plans here.